EDELRIS

- Look at this sample of chemical structures: it gives you an idea of the beauty and diversity of chemistries EDELRIS scientists have been tackling over the years for our clients. - There are many more we can’t show! - Even though most were challenging, our expert teams🏆 always made it to the finish line with perseverance and creativity, all to the satisfaction of our valued clients and partners! - Edelris embraces challenges and always emerges stronger💪. - When it comes to your organic synthesis needs, Edelris is the solution you can always rely on🤝! #organicsynthesis #medicinalchemistry #drugdiscovery #medchem #naturalproductsynthesis #molecularglues #drugdevelopment #chemistry

At EDELRIS, our team is continually expanding and evolving, embracing new ideas and perspectives to attain innovative results. We are delighted to extend a warm welcome to Maeva, Lydia, Alexandre, and Axel, our exceptional new colleagues at Edelris. Their talent and fresh insights will contribute to our ongoing success and innovation. We look forward to achieving great things together! #recherche #talents #innovation #hiring #research 

EDELRIS is thrilled that the second publication on Mark Wever’s PhD research has been released. Mark’s PhD research was part of the EU-financed AntiHelix Project (grant no. 859853), and his “home” laboratory was in Lyon under the guidance of Edelris researchers Vincent Rodeschini and Didier Roche and co-hosted with the team of Jean-Francois Poisson at Université Grenoble Alpes. Together with his co-researchers from the Antihelix project consortium at Sheffield University (Francesca Romana Scommegna, special thanks to Cyril Sanders for hosting Mark in his Sheffield Uni labs during a secondment) & Ludwig-Maximilians-Universität München (Sara Egea Rodríguez), Mark was able to describe the first de novo discovery, via an X-ray crystallographic fragment-based (FB) screen (XChem, at DLS, Oxford), of DNA binding and unwinding inhibitors of the human helicase hPIF1. The results showed that hPIF1 is amenable to structure-based drug discovery, and the synthesized tool compounds will further help understand this target's implication in cancer development and treatment. Congratulations to Mark and the Antihelix consortium on publishing this important contribution to cancer research. https://lnkd.in/dXHZg8fU #cancerresearch #structurebaseddrugdiscovery #medicinalchemistry #medchem #research

At today's “Emergence of irreversible modulation in drug discovery” event in Cambridge, our “Chemical libraries & technologies” manager, Hugues Lemoine, will give a presentation on EDELRIS’s expertise in the “Design, synthesis and reactivity profiling of novel covalent libraries for chemical biology and drug discovery.” Please contact Hugues if you want to enrich your compound collections with 3D-rich, unique, and IP-free covalent binders. If you’re not at the event, then use busdev@edelris.com #covalentbinders #drugdiscovery #drugdevelopment #drugdesign #medicinalchemistry #innovation

EDELRIS actively engages in multiple European research collaborations, leveraging our R&D expertise in developing bioactive small molecular entities. These partnerships are instrumental in propelling our company forward, generating employment opportunities, and establishing valuable intellectual property. Furthermore, hosting foreign PhD students and post-docs in our research labs provides numerous enriching scientific experiences. Tomorrow, our CSO, Didier Roche, will participate in the “Destination Europe” roundtable discussion, where he will share, analyze, and discuss Edelris’s experiences as a partner in European collaborative research projects. This event is a part of the “Journée Collaborative 2024” (October 15) organized by Lyonbiopôle Auvergne-Rhône-Alpes. Didier will co-animate this session with Camille Ducki (Director of Research & Innovation, Grenoble Univ. Hospital) & Paul Kauffmann (CEO, MagIA diagnostics). For registration and more information on this event: https://lnkd.in/gmtGxrSk #researchcollaboration #innovation #researchanddevelopment #RandD

Next week, two exciting chemistry events are happening in the UK, and EDELRIS will participate! The RSC-BMCS/SCI co-organized “Targeting protein degradation 4” takes place at Cranfield University on October 15-16, and this will be an excellent opportunity to exchange on the ongoing developments and latest innovations in the market and at Edelris. In Cambridge, the British Pharmacological Society organizes the “Emergence of irreversible modulation in drug discovery” on October 16-17. Hugues Lemoine, Edelris’s manager of “Chemical libraries & technologies”, will give a presentation on Edelris’s expertise in the “Design, synthesis, and reactivity profiling of novel covalent libraries for chemical biology and drug discovery.” It will be an exciting time for him to participate in these 2 events with experts and key opinion leaders. If you are interested in screening for unique and IP-free molecular glues and enriching your collections with covalent binders for your biological targets, then Edelris is your partner of choice! Reach out to Hugues or contact us at busdev@edelris.com #molecularglues #covalentbinders #drugdiscovery #protac #drugdevelopment #drugdesign

Today, EDELRIS’s teams came together to show our support for #Pink October and all those battling breast cancer. Our coffee break was filled with an abundance of pink as teammates proudly sported their pink attire and showcased their baking skills with delightful pink treats! Early detection is key, and Edelris encourages everyone to prioritize regular self-examinations and mammography checks for women. You can refer to the following helpful links for more information and detailed guidance on self-examinations. Let's stand together in the fight against breast cancer! https://lnkd.in/dDn9AtMe https://lnkd.in/dmbDkcnB https://lnkd.in/eZK5VV4p Aujourd’hui, les équipes de EDELRIS se sont réunies pour montrer notre soutien à #Pink October et à tous ceux qui luttent contre le cancer du sein. Notre pause-café du matin débordait de rose, les équipes arborant fièrement leur tenue rose et présentant leurs compétences en délicieuses pâtisseries roses! Le dépistage précoce est essentiel, et Edelris encourage tout le monde à donner la priorité aux auto-examens réguliers et aux mammographies pour les femmes. Vous pouvez consulter les liens suivants pour obtenir plus d’information et des conseils détaillés sur les auto-examens. Unissons-nous pour lutter contre le cancer du sein! https://lnkd.in/dDn9AtMe https://lnkd.in/dmbDkcnB https://lnkd.in/eZK5VV4p #breastcancer #cancerdusein #fightbreastcancer #octobrerose #pinkoctober

EDELRIS is a strong and active partner in the education and training of our future scientists! As a partner of the EU-funded CAPSTONE_H2020 Research Consortium, we are delighted to see Rebecca Deprez’s PhD student Vasileios Fougiaxis publishing his first research article as “first-author.” In the frame of our collaboration with Rebecca, Vasileios spent inspiring time with Edelris’s medicinal chemistry experts to design and improve new ERAP1 aminopeptidase inhibitors. Vasileios will defend his PhD thesis at the University of Lille on October 25th. We wish him all the best for his future and career! Access to the full article: https://lnkd.in/d3d7DPv5 #research #medchem #medicinalchemistry #drugdiscovery #fragmentbaseddrugdiscovery #FBDD

Great news - The collaboration with EDELRIS has produced excellent results!! USP8 regulates the ubiquitination level and fate of EGFR, and its deregulation is associated with many diseases, including cancers and Cushing’s disease. Cushing’s disease is a rare and severe disease in which pituitary tumors cause an excess of adrenocorticotropic hormone (ACTH), resulting in an increased release of cortisol and adrenal androgens. New results were presented this week by Marie-Odile Fauvarque Marras (Université Grenoble Alpes, CEA, Inserm, IRIG, BGE UA13) at the EMBO workshop on Ubiquitin and ubiquitin-like proteins in health and disease. The aim of the study was to identify new ligands of USP8 to investigate the role of the USP8::CHMP1B complex in endocytosis, oncogenesis, and ACTH secretion. In the frame of the AAPG2020 DruggingUSP8 project coordinated by Marie-Odile, Edelris used its ASMS platform to screen two truncated domains, MBP-tagged MIT and RHO domains of USP8. With our expertise, specific binders of the RHO and MIT domains, originating from Edelris's +2M unique compound collection, were identified. This constitutes the first milestone in providing tool compounds to elucidate the role of USP8 in Cushing’s disease. #CushingDisease #thiscushing #biochemistry #drugdevelopment #toolcompounds #drugdiscovery

EDELRIS is on site at the DoT! ✔ Need expert screening for your biological targets? Then let our AS-MS talents find the hits from our unique 2Mio+ collection of sp3-enriched compounds (Keymical Space)! ✔ Looking for new chemical matter? Take a look at our non-exclusive Keymical Collections, designed and produced in-house (fragments, HTS compounds, DEL-ready BB and covalent compounds). Exclusive collections can also be put together to suit your needs! ✔ Already found your hits? Let our exceptional medicinal chemists take you to the next level and beyond! Nathalie Joly and Jean-Yves Ortholand can't wait to show you how the powerful EDEN (Edelris Discovery ENgine) can help you reach new heights in drug discovery. 💊 #drugdiscovery #medicinalchemistry #smallmolecules #molecularglues #kinases #drugdesign #drugdevelopment